AzTrials
AzTrials

Preterm LaborNCT03253016

The Impact of Cervical Cerclage or Vaginal Progesterone on Vaginal Microbiome Distribution

A study testing vaginal swab -microbiome test and blood test for cytokines in people with Preterm Labor, run by Western Galilee Hospital-Nahariya at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

A comparative evaluation to evaluate the correlation between cervical cerclage or vaginal progesterone and maternal vaginal microbiome distribution during pregnancy Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Preterm Labor
What is being tested?
vaginal swab -microbiome test and blood test for cytokines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteIsrael
Study dates
26 Mar 2017to Jan 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • G- roup 1 - Pregnant women with a singleton gestation and cervical cerclage at 12-14 weeks of gestation due to obstetrical history characteristic of cervical insufficiency G- roup 2 - Pregnant women with a singleton gestation at 12-14 weeks of gestation without a history of cervical insufficiency
  • Group 3 - Pregnant women treated with progesterone due to previous preterm labor without cerclage

Who cannot join

  • A- cute cervical insufficiency P- roven or suspected chorioamnionitis P- remature rupture of membranes F- etal structural abnormality G- estation beyond 15 weeks A- ntibiotic usage in the past month P- robiotic use in the past month R- eported autoimmune disease or immunosuppressive disorder

Trial locations and contacts

1 site in 1 country.

Maya Wolf, MD contact

972-507887800

Mayaf@gmc.gov.il

Israel1 site, 1 recruiting
  • Galil Medical Center

    Nahariya, Israel

    Maya Wolf, MD, 972-507887800, homesickid@yahoo.com

    Recruiting

Other trials in Israel

About this study

Official title: A Comparative Evaluation to Evaluate the Correlation Between Cervical Cerclage or Vaginal Progesterone and Maternal Vaginal Microbiome Distribution During Pregnancy

A comparative evaluation to evaluate the correlation between cervical cerclage or vaginal progesterone and maternal vaginal microbiome distribution during pregnancy

Read the detailed description

Cervical insufficiency is primarily a clinical diagnosis, characterized by painless cervical dilation leading to recurrent second-trimester pregnancy losses/births of otherwise normal pregnancies.

Adverse perinatal events associated with cervical insufficiency include prolapse of the fetal membranes into the vagina, intra-amniotic infection, preterm premature rupture of membranes, preterm labor and fetal loss.

Congenital and acquired cervical abnormalities increase the risk of cervical insufficiency; Acquired risk factors are more common and include cervical trauma during delivery, rapid mechanical cervical dilation before a gynecologic procedure or treatment of cervical intraepithelial neoplasia (1). Congenital abnormalities include genetic disorders affecting collagen, uterine anomalies and in the past - in utero diethylstilbestrol (DES) exposure (2, 3).

The diagnosis of cervical insufficiency is based on either

  • History of painless cervical dilatation with preterm (midtrimester) delivery
  • History of prior second-trimester pregnancy losses or preterm births and cervical length ≤25 mm on transvaginal ultrasonography examination or advanced cervical changes on physical examination before 24 weeks of gestation.

The diagnosis of cervical insufficiency is usually limited to singleton gestations. In addition, preterm labor, infection, abruptio placenta, and bleeding placenta previa should be excluded, as these disorders could account for biochemically mediated cervical ripening leading to second-trimester pregnancy loss or preterm delivery independent of structural/anatomic cervical weakness [4].

The American College of Obstetricians and Gynecologists (ACOG) defines cervical insufficiency as the inability of the uterine cervix to retain a pregnancy in the second trimester in the absence of clinical contractions, labor, or both [5].

Women with a history of cervical insufficiency should be considered for history-indicated cerclage in future pregnancies at 12 to 14 weeks of gestation (6, 7).

Cerclage placement is considered a benign proce¬dure, the risks of such procedure include - cervical lacerations at the time of delivery, the need for cesarean delivery because of the inability of the cervix to dilate secondary to cervical scarring and dystocia, infection, cervical cerclage displacement Nonsurgical interventions have been advocated for patients with presumed cervical insufficiency. Progesterone supplementation appears to reduce the rate of spontaneous singleton preterm birth in women who have had a previous spontaneous preterm singleton birth and in women with a short cervix on ultrasound examination in the current pregnancy (8). In women with a prior preterm birth, continuing progesterone supplementation after placement of a cerclage has not been proven to be useful, but available data are limited.

Most cerclages are placed via a transvaginal approach. The transabdominal approach is more invasive, but allows higher placement, while transvaginal cerclages often end up distal to the internal os. The two most common transvaginal techniques for cerclage are McDonald procedure and Shirodkar procedure. The McDonald procedure is easier to perform and remove. The bulk of data show no significant differences in pregnancy outcome between the two procedures (6, 9, 10).

McDonald cerclage -

  • The procedure is begun by grasping the anterior and posterior lips of the cervix with one or two ring forceps
  • A curved needle loaded with large caliber non-absorbable synthetic suture (at least number 1 or 2 braided or monofilament) is inserted at 12 o'clock, at least 2 cm above the external os.
  • Four to six passes of a purse-string suture are taken circumferentially around the entire cervix as high as safely possible.
  • The two ends of the suture are then tied securely and cut, leaving the ends long enough to grasp with a clamp when it is time to remove it (11).

During gestation, the female body undergoes hormonal, immunological, and metabolic changes to support fetal growth and development. There are noticeable changes in the microbiota at different body sites during pregnancy.

The human vaginal microbiota is a key component in the defense system against microbial and viral infections. The vaginal microbiome is dominated by many species including Lactobacillus and members of the Clostridiales, Bacteriodales, and Actinomycetales. Specifically, these lactic acid producing bacteria can create a barrier against pathogen invasion by maintaining a low pH (< 4.5) and by secreting metabolites that play an important role in inhibition of bacterial and viral infection in the urogenital tract.

The vaginal microbiome undergoes significant changes during pregnancy, including a significant decrease in overall diversity, increased stability and enrichment with Lactobacillus species (12). These correlate with a decrease in the vaginal pH and an increase in vaginal secretions. Vaginal microbial compositions were found to differ according to gestational age, while the communities at the later stages of pregnancy resembled those of the non-pregnant state. The dominant Lactobacillus species in pregnancy varies according to ethnic group. In women whose vaginal microbiota is not lactobacilli-dominated anti-bacterial defense mechanisms are reduced. The enhanced proliferation of pathogenic bacteria plus degradation of the cervical barrier increase bacterial passage into the endometrium and amniotic cavity and trigger preterm myometrial contractions (13).

About 2 million cervical cerclages are performed annually to prevent preterm birth. Two types of suture material are used for cerclage: monofilament or multifilament braided. Braided sutures are most frequently used, although no evidence exists to favor them over monofilament sutures. Birth outcomes in a retrospective cohort of 678 women receiving cervical cerclage in five UK university hospitals showed that braided cerclage was associated with increased intrauterine death (15% versus 5%; P = 0.0001) and preterm birth (28% versus 17%; P = 0.0006) compared to monofilament suture. A prospective study explored the vaginal microbiome in women at risk of preterm birth because of short cervical length (≤25 mm) who received braided (n = 25) or monofilament (n = 24) cerclage under comparable circumstances (14). Braided suture induced a persistent shift toward vaginal microbiome dysbiosis characterized by reduced Lactobacillus spp. and enrichment of pathobionts. Vaginal dysbiosis was associated with inflammatory cytokine and interstitial collagenase excretion into cervicovaginal fluid and premature cervical remodeling. Monofilament suture had comparatively minimal impact upon the vaginal microbiome and its interactions with the host. The shift of the human vaginal microbiome toward dysbiosis correlated with preterm birth (14).

Conditions
Preterm Labor
Being tested
vaginal swab -microbiome test and blood test for cytokines
Medical subject headings
Obstetric Labor, Premature

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • vaginal swab -microbiome test and blood test for cytokinesDiagnostic test

    vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms

Study groups in NCT03253016
Study groupRoleWhat they receive
cervicall cerclageExperimentalto test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32
Receives: Diagnostic Test: vaginal swab -microbiome test and blood test for cytokines
vaginal progesteroneExperimentalto test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32
Receives: Diagnostic Test: vaginal swab -microbiome test and blood test for cytokines
contolNo interventionto test vaginal microbiome during pregnancies without cerclage or progesterone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. vaginal microbiome distribution between the arms

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Aug 2017
  2. Study start26 Mar 2017
  3. Primary completionJan 2020 (estimated)
  4. Study completionJan 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03253016
Sponsor's protocol ID
0196-16-NHR
Status last verified
Mar 2017
First submitted
14 Aug 2017
Last updated
17 Aug 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing vaginal swab -microbiome test and blood test for cytokines in people with Preterm Labor, run by Western Galilee Hospital-Nahariya at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Maya Wolf, MD (972-507887800, Mayaf@gmc.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

vaginal microbiome distribution between the arms (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in